chloroquin
known
sinc
apart
wellknown
antimalari
effect
drug
interest
biochem
properti
might
appli
viral
infect
chloroquin
exert
direct
antivir
effect
inhibit
phdepend
step
replic
sever
virus
includ
member
flavivirus
retrovirus
coronavirus
beststudi
effect
hiv
replic
test
clinic
trial
moreov
chloroquin
immunomodulatori
effect
suppress
productionreleas
tumour
necrosi
factor
interleukin
mediat
inflammatori
complic
sever
viral
diseas
review
avail
inform
effect
chloroquin
viral
infect
rais
question
whether
old
drug
may
experi
reviv
clinic
manag
viral
diseas
aid
sever
acut
respiratori
syndrom
afflict
mankind
era
globalis
chloroquin
known
sinc
specif
synthesis
use
antimalari
agent
chloroquin
subsequ
shown
immunomodulatori
properti
encourag
applic
treatment
autoimmun
diseas
rheumatoid
arthriti
specif
patholog
chloroquin
hydroxyanalogu
hydroxychloroquin
repres
valid
contribut
avail
pharmacolog
tool
sinc
prove
abl
slow
progress
diseas
show
limit
toxic
unfortun
chloroquin
gradual
dismiss
antimalari
therapi
prophylaxi
due
continu
emerg
chloroquineresist
plasmodium
falciparum
strain
howev
toler
low
cost
immunomodulatori
properti
chloroquinehydroxychloroquin
associ
biochem
effect
suggest
potenti
use
viral
infect
whose
symptom
may
result
inflammatori
respons
rais
question
whether
old
drug
whose
parent
compound
quinin
isol
late
centuri
bark
tropic
cinchona
tree
may
experi
reviv
clinic
manag
viral
diseas
era
globalis
chloroquin
hydroxychloroquin
weak
base
known
affect
acid
vesicl
lead
dysfunct
sever
enzym
extracellularli
chloroquinehydroxychloroquin
present
mostli
proton
form
due
posit
charg
incap
cross
plasma
membran
howev
nonproton
portion
enter
intracellular
compart
turn
becom
proton
manner
invers
proport
ph
accord
hendersonhasselbach
law
thu
surpris
chloroquinehydroxychloroquin
concentr
within
acid
organel
endosom
golgi
vesicl
lysosom
ph
low
chloroquinehydroxychloroquin
molecul
posit
charg
andor
action
multidrug
resist
protein
cell
surfac
drug
transport
belong
atpbind
cassett
famili
also
includ
thoroughli
studi
pglycoprotein
well
establish
weak
base
increas
ph
lysosom
transgolgi
network
tgn
vesicl
disrupt
sever
enzym
includ
acid
hydrolas
inhibit
posttransl
modif
newli
synthesis
protein
chloroquinemedi
rise
endosom
ph
modul
iron
metabol
within
human
cell
impair
endosom
releas
iron
ferrat
transferrin
thu
decreas
intracellular
concentr
iron
decreas
turn
affect
function
sever
cellular
enzym
involv
pathway
lead
replic
cellular
dna
express
differ
gene
gener
mechan
viral
inhibit
chloroquin
chloroquinehydroxychloroquin
impair
replic
sever
virus
interact
endosomemedi
viral
entri
late
stage
replic
envelop
virus
figur
virus
enter
target
cell
endocytosi
process
target
viru
lysosom
compart
low
ph
along
action
enzym
disrupt
viral
particl
thu
liber
infecti
nucleic
acid
sever
case
enzym
necessari
viral
replic
chloroquin
shown
inhibit
differ
virus
requir
phdepend
step
entri
borna
diseas
viru
minut
viru
mice
mvmp
avian
leucosi
viru
particular
interest
human
patholog
report
chloroquin
inhibit
uncoat
hepat
viru
thu
block
entir
replic
cycl
envelop
virus
posttransl
modif
envelop
glycoprotein
occur
within
endoplasm
tgn
vesicl
process
involv
proteas
glycosyltransferas
requir
low
ph
line
phdepend
event
chloroquin
seen
inhibit
bud
mayaro
viru
particl
induc
accumul
noninfecti
herp
simplex
viru
particl
tgn
chloroquin
also
inhibit
replic
member
flavivirida
famili
affect
normal
proteolyt
process
flaviviru
prm
protein
result
viral
infect
impair
final
chloroquin
induc
product
noninfecti
retroviru
particl
shown
avian
reticuloendotheliosi
viru
reva
mechan
inhibit
seem
inhibit
glycosyl
envelop
glycoprotein
discuss
accumul
chloroquinehydroxychloroquin
lymphocyt
macrophag
result
antiinflammatori
properti
led
clinic
use
condit
rheumatoid
arthriti
lupu
erythematosu
sarcoidosi
last
characteris
overproduct
tumour
necrosi
factor
alveolar
macrophag
chloroquinehydroxychloroquin
reduc
secret
proinflammatori
cytokin
particular
shown
murin
macrophag
cell
line
mous
periton
macrophag
human
peripher
blood
mononuclear
cell
human
whole
blood
sever
mechan
evok
explain
chloroquinehydroxychloroquineinduc
inhibit
product
monocytemacrophag
disrupt
cellular
iron
homeostasi
inhibit
mrna
express
inhibit
pretransl
stage
nonlysosomotrop
mechan
posttransl
stage
block
convers
cellassoci
solubl
matur
form
apart
inhibit
product
stimul
monocytemacrophag
chloroquin
also
decreas
surfac
express
receptor
human
monocyt
cell
line
henc
receptormedi
signal
result
impair
signal
shown
figur
studi
review
show
chloroquin
hydroxychloroquin
invitro
antivir
effect
antiinflammatori
properti
may
interest
viral
infect
associ
inflamm
andor
immun
activ
analys
potenti
effect
drug
diseas
safeti
criteria
met
estim
riskbenefit
ratio
chloroquinehydroxychloroquin
wellstudi
toxic
profil
halfcenturylong
use
drug
therapi
malaria
demonstr
safeti
acut
administr
chloroquin
human
be
use
chloroquinehydroxychloroquin
rheumat
diseas
antimalari
prophylaxi
show
low
incid
advers
event
chronic
administr
drug
period
year
case
seriou
toxic
effect
macular
retinopathi
depend
cumul
dose
rather
daili
dose
perman
damag
may
prevent
regular
visual
monitor
treatment
recent
studi
provid
encourag
result
safeti
high
dosag
drug
mg
chloroquin
base
per
day
even
pregnanc
conclud
chloroquinehydroxychloroquin
administr
present
limit
wellprevent
toxic
may
thu
result
low
riskbenefit
balanc
least
use
lifethreaten
condit
henceforth
discuss
potenti
use
old
drug
treatment
two
infecti
diseas
pose
seriou
threat
public
health
era
globalisationi
aid
sever
acut
respiratori
syndrom
sar
diseas
caus
envelop
rna
virus
share
clinic
manifest
like
mediat
immun
reaction
host
test
condit
intend
mimic
best
possibl
clinic
situat
chloroquinehydroxychloroquin
capabl
inhibit
hiv
vitro
abil
shown
either
overload
cell
high
concentr
chloroquinehydroxychloroquin
infect
mimic
drug
buildup
take
place
tissu
patient
subject
chronic
treatment
keep
hivinfect
cell
constant
incub
concentr
chloroquin
detect
whole
blood
individu
chronic
treat
drug
antihiv
activ
chloroquin
shown
cell
line
model
also
peripher
blood
lymphocyt
monocyt
ie
cell
cultur
model
cellular
uptak
chloroquin
closer
condit
occur
vivo
condit
possibl
obtain
level
inhibit
viral
replic
hydroxychloroquin
antivir
activ
vivo
report
two
phase
ii
clinic
trial
first
trial
small
randomis
doubleblind
placebocontrol
pilot
studi
patient
patient
per
arm
antiretrovir
treatmentna
hydroxychloroquin
administr
week
result
mean
log
reduct
plasma
rna
copi
number
well
decreas
interleukin
concentr
wherea
placebo
effect
rna
interleukin
second
trial
also
small
randomis
doubleblind
trial
compar
effect
hydroxychloroquin
zidovudin
monotherapi
mean
log
reduct
sinc
eight
peopl
zidovudin
group
none
individu
hydroxychloroquin
group
show
increas
rna
level
cultur
viru
level
therapi
data
consist
hypothesi
resist
hydroxychloroquin
may
easili
develop
oppos
wellknown
develop
resist
monotherapi
antiretrovir
zidovudin
result
larger
clinic
trial
necessari
accur
analysi
possibl
discrep
effect
chloroquin
vitro
hivinfect
individu
us
recent
shown
chloroquin
nontox
clinic
achiev
concentr
invitro
activ
primari
isol
belong
differ
clade
mechan
antihiv
effect
chloroquinehydroxychloroquin
reduct
infect
newli
produc
virion
review
savarino
et
al
antivir
effect
chloroquin
associ
reduc
product
heavili
glycosyl
epitop
locat
envelop
glycoprotein
surfac
fundament
viru
infect
effect
like
attribut
increas
ph
tgn
impair
function
glycosyltransferas
involv
posttransl
process
hiv
glycoprotein
hiv
glycosyl
may
therefor
repres
new
target
antiretrovir
therapi
viral
envelop
glycosyl
mediat
cellular
enzym
inhibit
may
explain
broad
spectrum
invitro
antihiv
activ
chloroquin
major
subtyp
effect
chloroquinehydroxychloroquin
cellular
rather
viral
enzym
may
also
result
low
propens
resist
develop
chloroquinehydroxychloroquin
probabl
inhibit
viral
replic
mechan
differ
current
use
antiretrovir
drug
applic
studi
combin
antiretrovir
drug
use
chloroquin
combin
antiretrovir
theoret
support
observ
chloroquin
also
show
antihiv
activ
vitro
toward
isol
patient
therapeut
failur
multidrugresist
profil
first
hydroxychloroquin
addit
vitro
antihiv
effect
zidovudin
second
chloroquin
exert
vitro
addit
effect
combin
hydroxyurea
plu
didanosin
hydroxyurea
plu
zidovudin
tcell
line
monocyt
primari
tcell
didanosinehydroxyureahydroxychloroquin
combin
especi
attract
develop
countri
due
low
cost
test
clinic
singapor
open
studi
initi
patient
start
studi
six
withdrawn
due
noncompli
remain
patient
rna
plasma
level
decreas
mean
log
week
smaller
studi
didanosin
hydroxyureachloroquin
rna
remain
lower
mean
log
week
open
pilot
studi
yet
allow
determin
contribut
chloroquinehydroxychloroquin
viral
load
drop
howev
conclud
addit
chloroquinehydroxychloroquin
hydroxyurea
didanosin
potenti
safe
thu
encourag
design
larger
studi
multipl
arm
possibl
hypothesis
chloroquin
may
find
potenti
applic
prevent
mothertochild
transmiss
mtct
hiv
breastfeed
problem
still
far
solv
resourcepoor
countri
one
us
report
accumul
chloroquin
colostrum
cell
mother
take
mg
chloroquin
daili
hypothesis
high
degre
chloroquin
accumul
mammari
cell
activ
replic
may
allow
decreas
milk
viral
load
andor
infect
milk
henc
may
lower
risk
breastfeedingrel
transmiss
account
onethird
onehalf
mtct
therefor
charg
chloroquin
administr
reduc
genom
exposur
studi
set
placebocontrol
pilot
studi
breastfeed
mother
receiv
togeth
infant
peripartum
nevirapin
assess
whether
daili
chloroquin
administr
compar
placebo
administr
mother
earli
month
breastfeed
may
result
decreas
rna
milk
level
andor
decreas
ex
vivo
infect
virion
isol
milk
chloroquinehydroxychloroquineinduc
suppress
synthesi
proinflammatori
cytokin
may
benefici
decreas
inappropri
immun
activ
characterist
hiv
infect
may
particularli
use
peopl
hivaid
develop
world
probabl
due
concomit
infect
present
higher
level
product
immun
activ
develop
world
chloroquin
hydroxychloroquin
studi
particularli
area
high
preval
southern
africa
inde
use
invitro
stimul
rate
transcript
activ
higher
enhanc
capac
respond
may
relat
extra
nfkappab
bind
site
present
long
termin
repeat
genom
base
effect
chloroquinehydroxychloroquin
sever
envelop
virus
immun
activ
rais
hypothesi
drug
might
use
clinic
manag
sar
present
attempt
treat
diseas
known
antivir
drugsnam
ribavirin
oseltamivirha
inconclus
corticosteroid
may
benefit
control
inflammatori
respons
lung
level
may
also
caus
uncontrol
immunodepress
result
pulmonari
superinfect
caus
agent
sar
recent
describ
new
coronaviru
recent
studi
support
idea
coronavirida
infect
target
cell
endocyt
pathway
chloroquin
might
inhibit
replic
hypothesis
chloroquin
black
arrow
inhibit
interleukin
product
might
block
subsequ
cascad
event
lead
ard
treat
nocodazol
microtubuledepolymeris
agent
block
transport
earli
late
endosom
produc
decreas
amount
antigen
result
indic
endosom
transport
need
infect
cell
treat
chloroquin
express
decreas
amount
antigen
preliminari
data
obtain
group
confirm
report
show
chloroquin
potent
inhibit
replic
canin
coronaviru
therapeut
reachabl
concentr
c
buonavoglia
et
al
univers
bari
itali
unpublish
although
sar
coronaviru
distinct
uniqu
characterist
tempt
ask
whether
chloroquin
might
affect
sar
coronaviru
replic
well
antiinflammatori
properti
chloroquin
hydroxychloroquin
also
consid
clinic
worsen
individu
sar
week
appar
unrel
uncontrol
sar
coronaviru
replic
may
relat
immunopatholog
damag
model
take
account
role
proinflammatori
cytokin
could
help
interpret
event
figur
view
deriv
effect
porcin
respiratori
coronaviru
prcv
share
sar
coronaviru
abil
caus
diseas
similar
histopatholog
featur
symptomatolog
prcv
induc
sever
lung
damag
immunemedi
mechanismsi
probabl
increas
concentr
proinflammatori
cytokin
interleukin
whose
role
induc
lung
damag
prove
use
adenovir
vector
anim
model
ground
think
associ
interleukin
concentr
diseas
sever
also
test
store
sampl
human
patient
sar
confirmatori
result
obtain
would
reason
consid
chloroquinehydroxychloroquin
suppress
interleukin
product
purpos
effort
develop
anim
model
sar
would
welcom
model
would
help
clarifi
immunemedi
compon
symptom
diseas
well
test
chloroquin
immunomodulatori
drug
studi
could
also
lay
groundwork
suggest
chloroquin
consid
treatment
viral
infect
involv
immunopatholog
present
difficult
answer
question
whether
old
chloroquin
abl
live
second
youth
due
main
effecti
rais
endosom
phthe
drug
except
broad
spectrum
antimicrobi
activ
could
exploit
mani
infect
result
obtain
prophylaxi
q
fever
indic
chloroquinehydroxychloroquin
success
use
clinic
manag
infect
malaria
regard
viral
diseas
clear
drug
antivir
immunomodulatori
effect
warrant
particular
consider
effect
hiv
infect
best
studi
among
antivir
effect
chloroquinehydroxychloroquin
test
clinic
trial
antihiv
effect
chloroquinehydroxychloroquin
modest
least
vitro
addit
synergist
combin
select
antiretrovir
invitro
result
warrant
invivo
confirm
hivposit
individu
compar
longterm
antivir
effect
highli
activ
antiretrovir
therapi
regimen
without
chloroquin
hydroxychloroquin
studi
provid
encourag
result
may
lead
strategi
wherebi
coadministr
chloroquinehydroxychloroquin
allow
lower
dose
antiretrovir
lessen
cost
possibl
toxic
costlessen
would
cours
particularli
welcom
develop
countri
moreov
potenti
abil
chloroquin
inhibit
replic
drugresist
viral
isol
could
import
treatment
drugexperienc
hivposit
patient
develop
multipl
resist
antiretrovir
drug
thu
limit
therapeut
option
develop
countri
malaria
endem
concomit
administr
chloroquinehydroxychloroquin
highli
activ
antiretrovir
therapi
regimen
may
result
least
p
falciparum
still
suscept
chloroquin
decreas
incid
malaria
episod
advers
effect
hivinfect
peopl
especi
pregnanc
moreov
antiinflammatori
properti
chloroquin
may
temper
noxiou
immun
hyperactiv
characterist
hivaid
due
broad
spectrum
antivir
activ
well
suppress
effect
productionreleas
interleukin
chloroquinehydroxychloroquin
may
also
find
place
treatment
viral
infect
characteris
symptom
associ
inflammatori
process
andor
immunehyperactiv
believ
studi
devot
inhibitori
effect
chloroquin
infect
flavivirus
one
member
famili
hepat
c
viru
great
import
human
patholog
often
coinfect
individu
flavivirida
also
includ
sever
arthropodborn
virus
yellow
fever
viru
west
nile
viru
recent
caus
epidem
north
america
final
want
share
scientif
commun
specul
hypothesi
chloroquinehydroxychloroquin
due
antivir
antiinflammatori
literatur
review
use
relev
medlin
search
term
variou
combin
chloroquin
viru
retroviru
cytokin
endothelium
macrophag
hiv
sar
nfkappa
b
coronaviru
proinflammatori
cytokin
ard
screen
articl
relev
review
refer
space
restrict
cite
review
articl
place
origin
manuscript
possibl
exclud
articl
whose
content
line
bulk
publish
inform
without
give
convinc
explan
rank
articl
basi
relev
date
public
journal
impact
factor
also
search
internet
relev
web
page
discard
edit
peopleinstitut
directli
involv
research
review
refer
refer
intend
provid
comprehens
list
chosen
best
highlight
critic
issu
properti
may
effect
sar
emphasis
need
test
cell
cultur
infect
sar
coronaviru
effect
chloroquin
well
substanc
possess
invitro
activ
member
coronavirida
famili
rememb
possibl
new
outbreak
sar
exclud
absenc
effect
inhibitor
sar
coronaviru
possibl
inhibit
least
vitro
replic
viru
would
repres
breakthrough
knowledg
sar
